Form 4: Rhythm Pharmaceuticals Executive Jennifer Kayden Lee Sells Shares Under 10b5-1 Trading Plan
SEC Form 4 Filing
EVP Jennifer Kayden Lee of Rhythm Pharmaceuticals sold shares of common stock on February 5, 2025, under a pre-arranged Rule 10b5-1 trading plan.
Summary
- Jennifer Kayden Lee, EVP, Head of North America at Rhythm Pharmaceuticals, sold shares of common stock on February 5, 2025.
- The sales were executed under a Rule 10b5-1 trading plan adopted on August 8, 2024.
- A total of 3,066 shares were sold in multiple transactions at varying prices.
- The weighted average sale prices were $60.0811, $61.0147 and $61.95 per share for different tranches of the sale.
- Following the reported transactions, Lee still beneficially owns 972 shares of Rhythm Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a routine SEC filing regarding stock sales by an executive. It doesn't inherently convey positive or negative sentiment.
Industry Context
Executive stock sales are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.
Stakeholder Impact
- The stock sale may have a minor impact on shareholders, potentially causing a slight decrease in stock price due to increased supply.
Key Dates
| Date | Description |
|---|---|
| 08/08/2024 | Date the Reporting Person adopted the Rule 10b5-1 trading plan |
| 02/05/2025 | Date of the stock sale transactions |
| 02/07/2025 | Date of the Form 4 filing |
Keywords
Rhythm Pharmaceuticals, Jennifer Kayden Lee, RYTM, Form 4, Stock Sale, 10b5-1 Trading Plan, Executive Compensation, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.